ClinicalTrials.gg
CompletedNCT01798628Updated Feb 26, 2013

A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

A Phase 1 interventional study of Treatment A: abiraterone acetate and Treatment B: abiraterone acetate in Healthy Volunteers, sponsored by Cougar Biotechnology, Inc.. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-26.

Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the effect of food on the pharmacokinetics (how the drug concentrations change over time) of abiraterone acetate 1000 mg when administered as a single dose in healthy male volunteers.

Read the detailed description

This is an open-label (identity of assigned study drug will be known), randomized (treatment sequences will be assigned by chance) study of a single dose of abiraterone acetate 1000 mg administered orally (by mouth) in approximately 36 healthy male participants under fasted and fed conditions. Three doses of abiraterone acetate will be administered with a 7-day washout period between each dose. The total study duration for each participant will be 21 days. Participants will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA): Treatment A = abiraterone acetate 1000 mg administered after a high-fat meal; Treatment B = abiraterone acetate 1000 mg administered after a low-fat meal; Treatment C = abiraterone acetate 1000 mg administered in the fasted state. No food will be ingested for 4 hours post-dose. Participants will be confined at the clinical research unit from the day prior to dosing until clinic discharge on the day following dosing in each treatment period. Serial pharmacokinetic samples will be collected and safety will be monitored throughout the study.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • Abiraterone acetate
  • Pharmacokinetics
03

In context

Lead sponsor

Cougar Biotechnology, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

First submitted after Cougar Biotechnology, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health as determined by no findings on medical history, physical examination, vital signs, 12-lead , and clinical laboratory measurements
  • within 18 kg/m2 to 32 kg/m2, inclusive
  • Non-tobacco users
  • Clinical laboratory values within protocol-defined parameters
  • Negative hepatitis panel (including surface antigen [HBsAg] and virus antibody [anti-HCV]),and negative (HIV) antibody screens
  • Negative test for selected drugs of abuse
  • Agrees to protocol-defined use of effective

Exclusion criteria

Exclusion Criteria:

  • Significant history or manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological or psychiatric disorder, as determined by the Principal Investigator
  • History or presence of an abnormal
  • History of stomach or intestinal surgery resection that would potentially alter absorption and/or excretion of orally administered drugs
  • Screening serum total testosterone of \<200 ng/dL
  • History of reaction to the study drug, related compounds or used in the formulation
  • Receipt of an drug within 5 half-lives or 30 days prior to Day -1, whichever is longer
  • Abnormal diet during the 30 days prior to Day 1
  • Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day -1
  • Planned donation of blood or plasma from Screening through Study Completion, Day 21
  • Receipt of blood products within 2 months prior to Day 1
  • History of protocol-defined alcohol abuse
  • Known or suspected use of illicit drugs within the last year
  • Use of any medication on a chronic basis
  • Use of any prescription medications/products or over-the-counter non-prescription preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by the Sponsor
  • Consumption of alcohol-containing foods or beverages within 24 hours prior to the first Check-in (Day -1)
  • Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion (Day21)
  • Consumption of caffeine-containing or grapefruit-containing foods or beverages within 72 hours prior to Day -1
  • Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or beverages from Day -1 through Study Completion (Day21)
  • Presence of sexual dysfunction or any medical condition that would affect sexual function
  • Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for the duration of the study
  • Presence of any condition that, in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in this study
  • Unwillingness to refrain from using any tobacco or nicotine-containing products during screening and throughout the study to Study Completion (Day 21)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Sequence ABC

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence ACB

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence BAC

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence BCA

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence CAB

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence CBA

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

  2. Time to maximum concentration of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

  3. Area under the concentration-time curve from time 0 to the last measurable concentration of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

  4. Area under the concentration-time curve extrapolated to infinity of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

  5. Apparent plasma terminal elimination rate constant of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

  6. Apparent terminal elimination half-life of abiraterone

    Time frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

Secondary outcomes

  1. Number of participants affected by an adverse event

    Time frame: Up to Day 21

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2012
First posted
Feb 26, 2013
Start
Sep 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Feb 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01798628
Responsible party
Sponsor
First posted
Feb 26, 2013
Start date
Sep 2009
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Feb 26, 2013

Study contacts

Cougar Biotechnology, Inc. Clinical Trial
study director · Cougar Biotechnology, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion